Foundayo

Orforglipron 3 mg

Orforglipron is the first oral, non-peptide GLP-1 receptor agonist in late-stage research. No injection. No cold chain. Taken as a daily tablet.

What it does

• GLP-1 receptor activation via the oral route — no needle
• Daily tablet, not a weekly injection
• The only product in the range that needs no pen
• Suited to anyone needle-averse

How it's delivered

3 mg tablet. Oral, once daily. No pen needed. Ships at ambient temperature.